Outcomes that Last
For more than a decade, HealthPrize programs have motivated people of all ages and backgrounds to take control of their treatment plans, reduce their cost of care and improve their health outcomes.
HealthPrize is highly engaging
Behavior change happens when we start to engage with our health. And engagement is at the core of the HealthPrize experience. It’s the scaffolding within which we enable our members to adopt the habits of better health and improve their outcomes.2
| Category | Result |
|---|---|
| Mean Daily Check-Ins | 6.43 days per week |
| Mean Time on Site per Visit | 2:03 minutes |
| Mean Time on Site per Month | 60 minutes |
| Mean Days Engaged Per Year | 329.4 days |
HealthPrize improves adherence
In a 2022 presentation at the American Thoracic Society, HealthPrize showed statistically significant improvements in medication adherence.3
| Category | Difference | P Value |
|---|---|---|
| Increase in Proportion of Days Covered (PDC) | ↑ 44% | (P < 0.0001) |
| Likelihood to Be Fully Adherent to Treatment | 2.51x | (P < 0.0001) |
| Lowered Risk of Discontinuing Index Treatment | ↓ 47% | (P < 0.0001) |
| Additional Days On Therapy | ↑ 82 Days | (P < 0.0001) |
HealthPrize reduces the cost of care
In the same presentation, HealthPrize members’ total cost of care was 24% lower than their matched controls (p=0.1184).3
HealthPrize increases Star Ratings
HealthPrize motivates members to develop and sustain the essential habits of optimal adherence. At 12 months, the adherence rate of the average HealthPrize member across all programs is 90.1% PDC.2
| PDC After 12 Months Enrollment | |
|---|---|
| Average PDC after 12 Months | 90.1% |
| Percentage of Previously Nonadherent Members who Became Adherent after 12 Months | 76.8% |
HealthPrize increases prescription fills
Across all HealthPrize programs for branded therapeutics, member engagement is associated with a 51% average lift in prescription fill rates.2
| Condition | Fill Lift | Data Source |
|---|---|---|
| Asthma | ↑ 45% | McKesson |
| Chronic Kidney Disease | ↑ 50% | Internal |
| Diabetes | ↑ 57% | Crossix |
| Hyperlipidemia | ↑ 39% | Crossix |
| Hypertension | ↑ 66% | McKesson |
References
1. 2023 Validation Report for HealthPrize. Validation Institute.
2. HealthPrize Member Registry. Data from all HealthPrize programs between January 2019 and May 2022.
3. Franchino-Elder J, Hayes V, Shaikh A, Firlik K. Assessment of medication adherence and the association with health care resource utilization and costs among HealthPrize-enrolled COPD patients, Presented at the American Thoracic Society 2022 International Conference.
Are you interested in improving adherence and reducing the cost of care in people with chronic conditions?
Give us 30 minutes to introduce you to how HealthPrize delivers outcomes that last.
Engagement first. Outcomes that last.